MONKEYPOX

This study tested whether giving a smaller dose of the MVA-BN (JYNNEOS) monkeypox vaccine under the skin works as well as the standard full dose given into the muscle. About 229 healthy adults aged 18 to 50 received either one-fifth or one-tenth of the standard dose under the ski…

This study tested the JYNNEOS mpox vaccine in 450 healthy teens and adults to see if it works as well in adolescents aged 12-17 as it does in adults. Participants received two shots under the skin. The main goal was to compare immune responses and check for side effects. Results …

This early-stage trial tested an RNA-based vaccine called BNT166a against mpox (monkeypox) in 96 healthy volunteers. The goal was to check safety and see if the vaccine triggers an immune response. Researchers looked for side effects like pain, fever, and fatigue, and monitored s…

This completed study monitored the safety of the MVA-BN (Jynneos) vaccine in 500 adults at high risk for monkeypox in the Democratic Republic of the Congo. Participants received two doses of the vaccine and were followed for up to 28 days after their last dose. The main goal was …

This study tested whether the drug tecovirimat is safe and effective for treating monkeypox (mpox). About 600 adults and children with confirmed mpox and active skin lesions took either tecovirimat or a placebo for 14 days, along with standard care. The main goal was to see how q…

This study looked at 320 people with mpox to check for eye complications. Researchers performed standard eye exams to see what eye problems might occur. The goal was to better understand how often and in what ways mpox affects the eyes.